Multiple Myeloma advances6th April 2006
Thalidomide should be added to the standard combination drug therapy for multiple myeloma reports the Lancet.
Its use led to longer event-free survival in a trial with 255 patients. Melphalan and prednisolone have been the standard treatment in Multiple Myeloma for over 40 years, adding thalidomide is the first advance in therapy since then.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Multiple Myeloma advances
Author: Sue Knights
Article Id: 208
Date Added: 6th Apr 2006